Invention Grant
- Patent Title: Humanized antibodies with anti-tumor activity
- Patent Title (中): 具有抗肿瘤活性的人源化抗体
-
Application No.: US13898666Application Date: 2013-05-21
-
Publication No.: US08901279B2Publication Date: 2014-12-02
- Inventor: Adam W. Clarke , Anthony G. Doyle , Philip A. Jennings , Norbert Kienzle , Matthew Pollard
- Applicant: Teva Pharmaceuticals Australia Pty Ltd
- Applicant Address: AU Macquarie Park, NSW
- Assignee: Teva Pharmaceuticals Australia Pty Ltd
- Current Assignee: Teva Pharmaceuticals Australia Pty Ltd
- Current Assignee Address: AU Macquarie Park, NSW
- Agency: Stradley Ronon Stevens & Young, LLP
- Priority: AU2009901129 20090316
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K16/30 ; C07K16/18 ; G01N33/574 ; C07K16/46
Abstract:
The present invention provides humanised antibodies and binding domains thereof with anti-tumor activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.
Public/Granted literature
- US20130280246A1 Humanized Antibodies with Anti-Tumor Activity Public/Granted day:2013-10-24
Information query
